$188M Cash Extends Cellectis Runway to Q4 2027; Positive Clinical Updates Emerge
Summary
Cellectis reported its first-quarter 2026 financial results, revealing a robust cash position of $188 million as of March 31, 2026, which is projected to provide a financial runway into Q4 2027. The company also provided significant clinical updates, including positive interim pivotal data from Allogene's ALPHA3 trial for cema-cel (originally Cellectis's UCART19), demonstrating 58.3% MRD negativity. This data serves as a strong validation for Cellectis's allogeneic CAR-T platform. Investors should closely watch for key upcoming catalysts in Q4 2026, which include the first interim analysis for the pivotal Phase 2 BALLI-01 trial for lasme-cel and the full Phase 1 dataset for eti-cel. The extended cash runway and clinical progress are positive developments for the clinical-stage biotechnology company.
At the time of this announcement, CLLS was trading at $3.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $272.6M. The 52-week trading range was $1.33 to $5.48. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.